Avid Bioservices (CDMO) Misses Q4 EPS by 1c; guides below views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023
June 21, 2023 4:07 PM EDT-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement --
-- Signed $55 Million in Net New Business Orders Resulting in a Record-High Backlog of $191 Million --
-- Mammalian Cell Manufacturing and Process Development Facility Expansions Currently Online and Active, Adding Approximately $120 Million of Annual Revenue Generating Capacity --
-- Cell and Gene Therapy Facility Expansion Remains on Schedule; Expected to be Online by End of Calendar Q3 2023 --
-- FY 2024 Revenue Guidance of Between... More
